Quince Therapeutics (formerly EryDel)
Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. Their Phase 3 lead asset, eDSP, for the treatment of the rare pediatric neurodegenerative disease Ataxia-Telangiectasia (A-T) is the first product in development that leverages their proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate dexamethasone sodium phosphate into the patient’s own red blood cells.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
www.quincetx.com
Related News
EryDel Announces Completion of Patient Enrollment in Phase 3 ATTeST Trial the Largest Clinical Study Ever Conducted in Ataxia Telangiectasia (AT)
EryDel Appoints Stan Musial as Chief Financial Officer
EryDel Appoints Ronan W. Gannon as Chief Commercial Officer
Sofinnova Partners leads EryDel’s €26.5 million financing
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.